Company news
Neurothera Labs Inc. (TSXV:NTLX) news
Neurothera Labs Inc. news releases on 6ix. Latest, Sep 23, 2026: NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration…
Press releases & updates
NeuroThera Highlights Enhancement of U.S. Patent Portfolio Through Collaboration with Clearmind Covering LSD, Ketamine and Ibogaine Combinations
September 23, 2026
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
September 2, 2026
NeuroThera Labs Achieves Significant Enrollment Momentum in SCI210 Autism Clinical Trial
August 31, 2026
Neurothera Labs Inc. Announces Share Consolidation
August 28, 2026
NeuroThera Labs Engages Dr. Reuter Investor Relations
August 27, 2026
NeuroThera-Clearmind Collaboration Advances MDMA-N-acylethanolamines IP for the Treatment of PTSD Amid Rising U.S. Federal Support for Psychedelic Innovation
August 24, 2026
Neurothera Labs Inc. Closes Final Tranche of Non-Brokered Private Placement
August 17, 2026
NeuroThera Labs Inc. Closes First Tranche of Non-Brokered Private Placement
August 12, 2026
NeuroThera Labs Granted Japanese Patent for Its Proprietary, Innovative Therapeutic Combination
August 12, 2026
NeuroThera Labs Launches Phase IIb Clinical Trial at Yale Child Study Center for First-of-its-kind Treatment for Tourette Syndrome
August 5, 2026
NeuroThera Labs' Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum Classical Workflow for Clinical Data Analytic
July 31, 2026
NeuroThera Labs Advances its Quantum Platform for Clinical Data Analytics on a Platform of an S&P 500 company
July 29, 2026
NeuroThera Labs Announces Initiation of Phase IIb Clinical Trial at Hannover Medical School in Germany for Innovative Treatment of Tourette Syndrome
July 15, 2026
NeuroThera Labs Announces Upsize to Private Placement
July 2, 2026
NeuroThera Labs Announces C$5,000,000 Private Placement of Units
June 30, 2026
NeuroThera Labs Inc. Announces Closing of Acquisition of Majority Stake in CliniQuantum Ltd.
June 3, 2026
Neurothera Labs Inc. Announces Closing Of Acquisition Of Majority Stake In Cliniquantum Ltd.
June 3, 2026
Neurothera Labs Inc. Provides Update On Proposed Acquisition Of Majority Stake In Cliniquantum Ltd.
May 27, 2026
Neurothera Labs Announces Adoption of Semi-Annual Reporting
May 20, 2026
Neurothera Labs Announces Continuance into Ontario
April 30, 2026
Neurothera Labs Engages bullVestor for Investor Relations Activities
April 23, 2026
Clearmind Medicine Announces Publication of Six Innovative Patents in Hong Kong for Next-Generation Psychedelic-Based Combination Therapies
March 17, 2026
NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy
March 16, 2026
Clearmind Medicine Announces Hong Kong Patent Filing for Depression Therapy
March 13, 2026
SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 12, 2026
NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease
March 11, 2026
Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd.
March 10, 2026
SciSparc Announces 1-for-9 Reverse Share Split
March 2, 2026
Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA
February 2, 2026
SciSparc Successfully Completes Acquisition of IP Portfolio, Advances Toward Immediate Commercialization
January 26, 2026
Neurothera Labs Announces Results of AGM
January 8, 2026
Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects
December 30, 2025
Neurothera Labs Signs Non-Binding Term Sheet to Acquire Majority Stake in a Quantum Algorithm Bio Data Analysis Company
December 2, 2025
SciSparc: Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
November 20, 2025
Neurothera Labs Announces Israeli Patent Application in Collaboration with Clearmind Medicine for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
November 19, 2025
Clearmind Medicine Files Israeli Patent for Novel Non-Hallucinogenic Neuroplastogen Treatment for Depression
November 17, 2025
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio
October 24, 2025